Followers | 85 |
Posts | 3089 |
Boards Moderated | 0 |
Alias Born | 03/03/2010 |
Tuesday, November 14, 2017 6:29:15 PM
Sounds like to me they shouldn't give up on this drug tho they simply need to adjust a few variables the dosing and timing that is even try every week as opposed to daily with a higher dosage and i bet money that this companies drug would have better results then the current drug on the market and not only that would only have to be taken once a week compared to everyday for the current drug...
The company also has Phase 2 Results due anytime
Some links
https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10089620/versartis-somavaratan-still-has-a-path-forward-cantor-r
https://www.fiercebiotech.com/biotech/phase-3-flop-puts-versartis-life-support
https://www.biospace.com/article/releases/versartis-twice-monthly-somavaratan-for-pediatric-growth-hormone-deficiency-to-be-featured-in-oral-and-poster-presentations-at-b-impe-2017-b-/
So clearly the drug does work like i said the company failed in my view by doing a limited study of only a single dosage and once every 2 weeks
They should have done different dosage levels and also at different intervals like a higher dosage every week
Basically they should have tried a few different options I belive that by increasing the dosage and giving it every week as opposed to every 2 weeks the results would be BETTER Then what is currently avaible on the market that has to be taken daily.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM